Global animal health company Virbac has reported a strong start to 2026, posting first-half revenue of €768 million and reaffirming its full-year financial guidance as demand for veterinary medicines, vaccines and animal health products remained strong across multiple regions.
The company reported 7.4% organic revenue growth at constant exchange rates and scope (CERS), highlighting continued momentum across its strategic product portfolio despite currency fluctuations and operational challenges in selected markets.
The results underline the resilience of the global animal health industry, where demand continues to be supported by rising pet ownership, expanding livestock production, preventive healthcare and increasing investment in animal welfare.
Strong Growth Across Strategic Product Platforms
Virbac said growth during the first six months of 2026 was driven by double-digit performance across its “Supercharge” strategic platforms, which include several of the company’s key innovation and growth initiatives.
Although foreign exchange movements affected reported revenues in some regions, underlying business performance remained robust, reflecting healthy customer demand and continued product adoption.
The balanced contribution from both companion animal and farm animal businesses demonstrates Virbac’s diversified portfolio, helping the company navigate changing market conditions while maintaining consistent growth.
Companion Animal Business Continues to Expand
The companion animal segment remained one of Virbac’s strongest growth drivers. Demand remained healthy for products supporting:
Parasite prevention
Vaccination
Dermatology
Pain management
Dental care
Nutritional health
Chronic disease management
The global pet healthcare market continues to benefit from long-term trends including increasing pet ownership, higher veterinary spending and growing awareness of preventive healthcare among pet owners.
As veterinary clinics continue to adopt newer diagnostic and treatment options, manufacturers such as Virbac are seeing sustained demand for innovative companion animal products.
Livestock Segment Delivers Balanced Growth
Virbac also reported positive performance across its farm animal business, supported by demand from cattle, swine, poultry and other livestock sectors.
Livestock producers worldwide continue to invest in disease prevention, vaccination programmes and productivity-enhancing health solutions as they respond to growing food demand and evolving disease risks.
Increasing attention to biosecurity, herd health management and responsible medicine use is also supporting continued investment in veterinary healthcare across commercial livestock operations.
The balanced performance across companion animal and livestock businesses provides Virbac with a diversified revenue base that reduces dependence on any single market segment.
North America, Europe and International Markets Lead Performance
The company reported broad-based growth across its major geographic regions. North America continued to benefit from strong demand for companion animal healthcare products and expanding veterinary services.
In Europe, steady market conditions and continued adoption of preventive healthcare products supported revenue growth despite economic uncertainty in some countries.
Virbac also reported encouraging performance across several international markets, reflecting increasing investment in veterinary healthcare in developing economies and expanding access to modern animal health products.
Although currency movements created some pressure on reported financial results, underlying business performance remained strong when measured at constant exchange rates.
Company Reaffirms Full-Year Guidance
Reflecting confidence in business performance, Virbac reaffirmed its financial outlook for the full year. The company expects continued growth during the second half of 2026, supported by:
Ongoing product innovation
Strong customer demand
Geographic expansion
Balanced companion animal and livestock portfolios
Continued investment in research and development
Management acknowledged that currency volatility and local operational challenges could continue to influence reported financial performance but indicated that the company’s overall growth trajectory remains positive.
Innovation Remains a Key Growth Driver
Virbac has continued investing in research, product development and manufacturing to strengthen its global animal health portfolio. The company operates across more than 100 countries and develops products covering:
Vaccines
Pharmaceuticals
Nutritional supplements
Diagnostics
Reproductive management
Dermatology
Dentistry
Parasiticides
Livestock health solutions
Innovation remains central to Virbac’s strategy as veterinary medicine increasingly focuses on preventive healthcare, precision diagnostics and improved animal welfare.
Positive Outlook for the Global Animal Health Industry
Virbac’s latest financial results reflect broader trends shaping the global animal health sector. Industry growth continues to be driven by:
Rising pet ownership worldwide
Increasing demand for preventive veterinary care
Growth in commercial livestock production
Expansion of vaccination programmes
Greater focus on food security
Improved disease surveillance
Higher investment in animal welfare
Advances in veterinary diagnostics and therapeutics
These long-term trends are expected to continue supporting demand for veterinary medicines and animal health products over the coming years.
What It Means for the Industry
Virbac’s first-half performance demonstrates that the global animal health market continues to show resilience despite economic uncertainty and currency headwinds. The company’s ability to generate growth across both companion animal and livestock businesses highlights the strength of diversified animal health portfolios and the increasing importance of preventive veterinary care.
As the industry continues to invest in innovation, digital technologies and next-generation healthcare solutions, companies with broad product portfolios and strong global market positions are expected to remain well placed for sustained long-term growth.
Key Highlights
-
First-half 2026 revenue: €768 million
-
Organic growth (CERS): 7.4%
-
Strong double-digit growth across strategic “Supercharge” platforms
-
Balanced growth from companion animal and livestock businesses
-
Positive performance across North America, Europe and international markets
-
Full-year financial guidance reaffirmed
-
Continued investment in innovation, research and global expansion
